Sinapultide

Drug Profile

Sinapultide

Alternative Names: Aerosolized KL4 surfactant; Aerosurf; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Scripps Research Institute
  • Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
  • Class Amino acids; Peptides; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome; Acute lung injury; Meconium aspiration syndrome; Adult respiratory distress syndrome; Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome
  • Preclinical Acute lung injury; Chronic obstructive pulmonary disease; Lung disorders; Reperfusion injury
  • No development reported Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Cystic fibrosis
  • Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

  • 29 Jun 2017 Top-line efficacy and adverse events data from a phase IIb trial in Neonatal respiratory distress syndrome released by Windtree Therapeutics
  • 12 Jun 2017 Windtree grants Lee's Pharmaceutical Holdings exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products
  • 12 Jun 2017 Windtree therapeutics and Lee's Pharmaceutical Holdings Ltd agree to co-promote and co-develop KL4 surfactant products in select Asian markets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top